APExBIO - Bardoxolone methyl|IKK inhibitor, potent antioxidant inflammation modulator|CAS# 218600-53-4
Schematic image of potential mechanism by which bardoxolone methyl... | Download Scientific Diagram
CDDO-Me | Cell Signaling Technology
Figure 2 | Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl
Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites | Journal of Medicinal Chemistry
Divulging the Intricacies of Crosstalk Between NF-Kb and Nrf2-Keap1 Pathway in Neurological Complications of COVID-19 | SpringerLink
Bardoxolone methyl
Cancers | Free Full-Text | Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer
Bardoxolone conjugation enables targeted protein degradation of BRD4 | Scientific Reports
Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells | Molecular Pharmacology
Frontiers | Dissecting the Crosstalk Between Nrf2 and NF-κB Response Pathways in Drug-Induced Toxicity
Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease | Signal Transduction and Targeted Therapy
Frontiers | Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages
Changes from baseline in body weight with bardoxolone methyl by... | Download Scientific Diagram
Bardoxolone methyl (RTA 402) | ≥99%(HPLC) | IκB/IKK inhibitor | AdooQ®
IKK Signaling | IkappaB Kinase
Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease - ScienceDirect
Can Activation of NRF2 Be a Strategy against COVID-19?: Trends in Pharmacological Sciences
Bardoxolone methyl (RTA 402) | Nrf2 Activator | MedChemExpress
